Eylea (aflibercept)

pCPA File Number: 20917

Negotiation Status:

Concluded with an LOI

Indication(s):

Macular edema secondary to branch retinal vein occlusion

Sponsor/Manufacturer:

Bayer Inc.

CDA-AMC Project Number:

SR0460-000

pCPA Engagement Letter Issued:

2017-02-22

Negotiation Process Concluded:

2017-03-13